H e m a t o lo g y E d u c a t io n - European Hematology Association
H e m a t o lo g y E d u c a t io n - European Hematology Association
H e m a t o lo g y E d u c a t io n - European Hematology Association
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
egress<strong>io</strong>n of tumor vessels, and appearance of basement<br />
membrane ghosts. Am J Pathol. 2004;165:35-52.<br />
70. Kane RC, Farrell AT, Saber H, Tang S, Williams G, Jee JM, et<br />
al. Sorafenib for the treatment of advanced renal cell carcinoma.<br />
Clin Cancer Res. 2006;12:7271-8.<br />
71. Cabebe E, Wakelee H. Sunitinib: a newly approved small-molecule<br />
inhibitor of ang<strong>io</strong>genesis. Drugs Today (Barc). 2006;42:<br />
387-98.<br />
72. Lin B, Podar K, Gupta D, Tai YT, Li S, Weller E, et al. The vascular<br />
endothelial growth factor receptor tyrosine kinase<br />
inhibitor PTK787/ZK222584 inhibits growth and migrat<strong>io</strong>n of<br />
multiple mye<strong>lo</strong>ma cells in the bone marrow microenvironment.<br />
Cancer Res. 2002;62:5019-26.<br />
73. Pandiella A, Carvajal-Vergara X, Tabera S, Mateo G, Gutiérrez<br />
N, San Miguel JF. Imatinib mesylate (STI571) inhibits multiple<br />
mye<strong>lo</strong>ma cell proliferat<strong>io</strong>n and potentiates the effect of common<br />
antimye<strong>lo</strong>ma agents. Br J Haematol. 2003;123:858-68.<br />
74. Dispenzieri A, Gertz MA, Lacy MQ, Geyer SM, Greipp PR,<br />
Rajkumar SV, et al. A phase II trial of imatinib in patients with<br />
refractory/relapsed mye<strong>lo</strong>ma. Leuk Lymphoma. 2006;47:39-42.<br />
75. Zangari M, Anaissie E, Stopeck A, Morimoto A, Tan N, Lancet<br />
J, et al. Phase II study of SU5416, a small molecule vascular<br />
endothelial growth factor tyrosine kinase receptor inhibitor, in<br />
patients with refractory multiple mye<strong>lo</strong>ma. Clin Cancer Res.<br />
2004;10:88-95.<br />
76. Kovacs MJ, Reece DE, Marcellus D, Meyer RM, Mathews S,<br />
Dong RP, et al. A phase II study of ZD6474 (Zactima, a selective<br />
inhibitor of VEGFR and EGFR tyrosine kinase in patients<br />
with relapsed multiple mye<strong>lo</strong>ma--NCIC CTG IND.145. Invest<br />
New Drugs. 2006;24:529-35.<br />
77. Podar K, Catley LP, Tai YT, Shringarpure R, Carvalho P,<br />
Hayashi T, et al. GW654652, the pan-inhibitor of VEGF receptors,<br />
b<strong>lo</strong>cks the growth and migrat<strong>io</strong>n of multiple mye<strong>lo</strong>ma<br />
cells in the bone marrow microenvironment. B<strong>lo</strong>od. 2004;<br />
103:3474-9.<br />
78. Prince HM, Honemann D, Spencer A, Rizzieri DA,<br />
Stadtmauer EA, Roberts AW, et al. Vascular endothelial<br />
growth factor inhibit<strong>io</strong>n is not an effective therapeutic strategy<br />
for relapsed or refractory multiple mye<strong>lo</strong>ma: a phase 2<br />
study of pazopanib (GW786034). B<strong>lo</strong>od. 2009;113:4819-20.<br />
London, United Kingdom, June 9-12, 2011<br />
79. Ramakrishnan V, Timm M, Haug JL, Kimlinger TK, Wellik LE,<br />
Witzig TE, et al. Sorafenib, a dual Raf kinase/vascular<br />
endothelial growth factor receptor inhibitor has significant<br />
anti-mye<strong>lo</strong>ma activity and synergizes with common antimye<strong>lo</strong>ma<br />
drugs. Oncogene. 2010;29:1190-202.<br />
80. Avet-Loiseau H, Li JY, Facon T, Brigaudeau C, Morineau N,<br />
Ma<strong>lo</strong>isel F, et al. High incidence of trans<strong>lo</strong>cat<strong>io</strong>ns<br />
t(11;14)(q13;q32) and t(4;14)(p16;q32) in patients with plasma<br />
cell malignancies. Cancer Res. 1998;58:5640-5.<br />
81. Keats JJ, Reiman T, Maxwell CA, Tay<strong>lo</strong>r BJ, Larratt LM, Mant<br />
MJ, et al. In multiple mye<strong>lo</strong>ma, t(4;14)(p16;q32) is an adverse<br />
prognostic factor irrespective of FGFR3 express<strong>io</strong>n. B<strong>lo</strong>od.<br />
2003;101:1520-9.<br />
82. Qing J, Du X, Chen Y, Chan P, Li H, Wu P, et al. Antibody-based<br />
targeting of FGFR3 in bladder carcinoma and t(4;14)-positive<br />
multiple mye<strong>lo</strong>ma in mice. J Clin Invest. 2009;119:1216-29.<br />
83. Grand EK, Chase AJ, Heath C, Rahemtulla A, Cross NC.<br />
Targeting FGFR3 in multiple mye<strong>lo</strong>ma: inhibit<strong>io</strong>n of t(4;14)positive<br />
cells by SU5402 and PD173074. Leukemia 2004;<br />
18:962-6.<br />
84. Paterson JL, Li Z, Wen XY, Masih-Khan E, Chang H, Pollett JB,<br />
et al. Preclinical studies of fibroblast growth factor receptor 3<br />
as a therapeutic target in multiple mye<strong>lo</strong>ma. Br J Haematol.<br />
2004;124:595-603.<br />
85. Trudel S, Ely S, Farooqi Y, Affer M, Robbiani DF, Chesi M, et<br />
al. Inhibit<strong>io</strong>n of fibroblast growth factor receptor 3 induces<br />
differentiat<strong>io</strong>n and apoptosis in t(4;14) mye<strong>lo</strong>ma. B<strong>lo</strong>od.<br />
2004;103:3521-8.<br />
86. Clezardin P. The antitumor potential of bisphosphonates.<br />
Semin Oncol. 2002;29:33-42.<br />
87. Wood J, Bonjean K, Ruetz S, Bellahcène A, Devy L, Foidart JM,<br />
et al. Novel antiang<strong>io</strong>genic effects of the bisphosphonate compound<br />
zoledronic acid. J Pharmacol Exp Ther. 2002;302:1055-61.<br />
88. Scavelli C, Di Pietro G, Cirulli T, Coluccia M, Boccarelli A,<br />
Giannini T, et al. Zoledronic acid affects over-ang<strong>io</strong>genic phenotype<br />
of endothelial cells in patients with multiple mye<strong>lo</strong>ma.<br />
Mol Cancer Ther. 2007;6:3256-62.<br />
89. Cocco C, Giuliani N, Di Car<strong>lo</strong> E, Ogn<strong>io</strong> E, Storti P, Abeltino M,<br />
et al. Interleukin-27 acts as multifunct<strong>io</strong>nal antitumor agent in<br />
multiple mye<strong>lo</strong>ma. Clin Cancer Res. 2010;16:4188-97.<br />
Hemato<strong>lo</strong>gy Educat<strong>io</strong>n: the educat<strong>io</strong>n programme for the annual congress of the <strong>European</strong> Hemato<strong>lo</strong>gy Associat<strong>io</strong>n | 2011; 5(1) | 279 |